Because we just dont know yet exactly what the long-term outcomes are for people who become pregnant while taking these medications. One early study suggested that using GLP-1 agonists during the first trimester didnt harm fetal development
Figure 1 2.1 IR and diabetes mellitus According to the 10th edition of the IDF Diabetes Atlas, 536.6 million people worldwide have diabetes, which means that more than 10.5% of the worlds adult population has the disease, and this number continues to grow, predicted to rise to 12.2% (783.2 million people) by 2045 ( Type 1 DM (T1DM) is caused by the primary loss of -cells the cells that release insulin and the complex autoimmune process of continuous insulin deficiency
It works by: Activating GLP-1 receptors in the brain, particularly in areas that regulate appetite and food intake, leading to reduced hunger and increased feelings of fullness Slowing gastric emptying , which prolongs the sensation of satiety after meals Improving insulin secretion in response to food intake and reducing glucagon release, which helps regulate blood glucose levels Promoting weight loss through these combined metabolic effects Wegovy is administered as a once-weekly subcutaneous injection and is primarily broken down by protein degradation pathways rather than through liver enzymes, which reduces the potential for drug-drug interactions
The Role of Dosage Escalation (Titration) One reason you might notice a sudden change in when or how side effects start is a change in your dosage
